Featured Publications
5‐Fluorouracil efficacy requires anti‐tumor immunity triggered by cancer‐cell‐intrinsic STING
Tian J, Zhang D, Kurbatov V, Wang Q, Wang Y, Fang D, Wu L, Bosenberg M, Muzumdar MD, Khan S, Lu Q, Yan Q, Lu J. 5‐Fluorouracil efficacy requires anti‐tumor immunity triggered by cancer‐cell‐intrinsic STING. The EMBO Journal 2021, 40: embj2020106065. PMID: 33615517, PMCID: PMC8013832, DOI: 10.15252/embj.2020106065.Peer-Reviewed Original ResearchConceptsAnti-tumor immunityTumor burdenSubsequent type I interferon productionHigh STING expressionIntratumoral T cellsT-cell depletionType I interferon productionI interferon productionLoss of STINGImmunocompetent hostsColorectal specimensT cellsSTING expressionBetter survivalHigh doseTherapeutic effectivenessHuman colorectal specimensMelanoma tumorsInterferon productionChemotherapeutic drugsMurine colonImmunityEfficacyStingsColon
2017
The cationic small molecule GW4869 is cytotoxic to high phosphatidylserine‐expressing myeloma cells
Vuckovic S, Vandyke K, Rickards DA, Winter P, Brown SHJ, Mitchell TW, Liu J, Lu J, Askenase PW, Yuriev E, Capuano B, Ramsland PA, Hill GR, Zannettino ACW, Hutchinson AT. The cationic small molecule GW4869 is cytotoxic to high phosphatidylserine‐expressing myeloma cells. British Journal Of Haematology 2017, 177: 423-440. PMID: 28211573, DOI: 10.1111/bjh.14561.Peer-Reviewed Original ResearchConceptsMyeloma cell linesMyeloma cellsMyeloma plasma cellsCell linesPlasma cellsPrimary myeloma samplesMalignant cellsMyeloma samplesGW4869Surface phosphatidylserine exposurePhosphatidylserine expressionPhosphatidylserine exposureCell surface phosphatidylserine exposureCellsBiochemical analysisCytotoxicSmall cationic moleculesIntracellular sidePhosphatidylserineCancerCell membraneSmall moleculesBrefeldin A
2016
miR-126 Regulates Distinct Self-Renewal Outcomes in Normal and Malignant Hematopoietic Stem Cells
Lechman ER, Gentner B, Ng SW, Schoof EM, van Galen P, Kennedy JA, Nucera S, Ciceri F, Kaufmann KB, Takayama N, Dobson SM, Trotman-Grant A, Krivdova G, Elzinga J, Mitchell A, Nilsson B, Hermans KG, Eppert K, Marke R, Isserlin R, Voisin V, Bader GD, Zandstra PW, Golub TR, Ebert BL, Lu J, Minden M, Wang JC, Naldini L, Dick JE. miR-126 Regulates Distinct Self-Renewal Outcomes in Normal and Malignant Hematopoietic Stem Cells. Cancer Cell 2016, 29: 214-228. PMID: 26832662, PMCID: PMC4749543, DOI: 10.1016/j.ccell.2015.12.011.Peer-Reviewed Original ResearchConceptsLeukemia stem cellsMiR-126Human acute myeloid leukemia stem cellsAcute myeloid leukemia stem cellsMyeloid leukemia stem cellsPI3K/Akt/mTORMiR-126 expressionAkt/mTORMalignant hematopoietic stem cellsMiR-126 regulationStem cellsMiR-126 targetsLSC activityLSC quiescenceAML samplesChemotherapy resistanceHematopoietic stem cellsHematopoietic stem cell cyclingMiRNA signatureCell cycle progressionLSC functionCycle progressionStem cell cyclingSignature miRNAsCell cycling